COVID-19 testing service now available from MDNA's UK laboratory: Click here ›
Who is at risk and who isn’t? With difficult to diagnose diseases like cancer, the unknown can sometimes be worse than knowing.
That’s why at MDNA Life Sciences we’re using our pioneering, patented Mitomic™ Technology to unlock the power of mitochondrial DNA and take the doubt out of diagnosis and decision-making. Putting a stop to unnecessary surgical pain, uncertainty and even death for millions of patients around the world.
MDNA Life Sciences. Beyond Doubt.
Through Mitomic™ Technology, we’re giving more people the reassurance of knowing yes or no, rather than maybe.
Inside the cells in our body are lots of tiny energy-producing mitochondria. Every mitochondria contains multiple copies of its own DNA. This mitochondrial DNA becomes mutated when the cells are stressed by diseases like cancer. Leaving a unique biomarker in the blood that we can detect and identify, even in the early stages of a condition. Helping to save lives by catching diseases like cancer fast enough for effective treatment.
We’ve developed a range of blood-based tests to accurately identify disease, before symptoms have even appeared. Our Mitomic™ test for prostate cancer, for example, has an unsurpassed 100% Negative Predictive Value for clinically significant cancer, making it the most accurate available today.
Our tests give doctors and patients the reassurance of a yes or no answer, helping to aid decisions and avoid unnecessary invasive surgery.
Since our breakthrough in mitochondrial genomics over 15 years ago, MDNA Life Sciences has been leading the way finding more accurate, non-invasive tests for conditions and diseases that are difficult to diagnose.
MDNA has appointed Shuwen Biotech Co. Ltd., a leader in developing and offering innovative diagnostic and personalized medicine products in China, as the exclusive license partner for the Mitomic® Prostate Test (MPT™) in China. On the heels of recent news that MDNA’s CE marked MPT™ Real-Time PCR kit is being made available through another 9 business partners covering 25 countries, this agreement is a key part of the global roll-out of MPT™ through a growing network of license partners and distributors.